Aquestive Therapeutics Inc (AQST) FY2025Q1 Earning Prediction
Aquestive Therapeutics Inc (AQST) is set to release its earnings performance on 05/12 16:01:00 ET in After Hours trading. Consensus forecasts predict a revenue of 12.23M and an earnings per share (EPS) of -0.17 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
AQST Transcript
The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
The earnings call highlights several concerning elements: a significant revenue decline, increased losses, and vague management responses in the Q&A. Despite preparations for ANNAFILM's launch, the lack of clear guidance on AdCom topics and potential impacts of new FDA personnel raises uncertainty. Additionally, the competitive pressure from existing products like EpiPen and NEFI, combined with potential operational risks, further contribute to a negative sentiment. The market may react negatively due to these uncertainties, leading to a predicted stock price movement of -2% to -8% over the next two weeks.
The earnings call reveals significant negative factors: a 28% revenue drop, increased net loss, and no share repurchase program. Legal risks and higher expenses further strain financial health. Despite a stable supply chain and Anaphylm's commercial readiness, uncertainties in payer coverage timelines and partnership details add concerns. Management's evasive responses in the Q&A amplify these uncertainties. The market is likely to react negatively, given the financial struggles and lack of clear positive catalysts. The prediction is a negative stock price movement of -2% to -8%.
AQST Slides
AQST Report
Frequently Asked Questions
What is the Aquestive Therapeutics Inc FY2025Q1 Earnings Release Date and Time?
Aquestive Therapeutics Inc (AQST) is scheduled to release its FY2025Q1 earnings report onMay 12, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Aquestive Therapeutics Inc FY2025Q1 Revenue and EPS?
Analysts' consensus predicts 12.23M in revenue and an EPS of -0.17 for Aquestive Therapeutics Inc's FY2025Q1.
What Does Intellectia's AI Predict for Aquestive Therapeutics Inc FY2025Q1 Earnings?
Intellectia's exclusive AI algorithms forecast a forAquestive Therapeutics Inc's FY2025Q1 earnings, with a prediction date of May 12, 2025. Aquestive Therapeutics Inc
How Can I Use This Earnings Prediction to Trade AQST Stock?
Leverage Intellectia's AI forecast to position trades ahead of theMay 12, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Aquestive Therapeutics Inc FY2025Q1?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
